Prof Scott Williams
Honorary Conjoint Professorial Fellow
The Sir Peter MacCallum Department of Oncology
182 Scholarly works
6 Projects
HIGHLIGHTS
2026
Journal article
Radiographic Progression Without Prostate-specific Antigen Progression in Metastatic Hormone-sensitive Prostate Cancer: A Retrospective Analysis of the ENZAMET Trial (ANZUP 1304)
DOI: 10.1016/j.euo.2026.01.0082026
Journal article
[177Lu]Lu-PSMA-617 in combination with pembrolizumab for treatment of metastatic castration resistant prostate cancer (PRINCE): a single-arm, phase 1b/2 study
DOI: 10.1016/S1470-2045(26)00017-32026
Journal article
Baseline Nodal Status on 68Ga-PSMA-11 Positron Emission Tomography/Computed Tomography in Men with Intermediate- to High-risk Prostate Cancer Is Prognostic for Treatment Failure: Follow-up of the proPSMA Trial
DOI: 10.1016/j.euo.2024.11.0062021
Research grants (international)
Identifying Genetic, Transcriptional and Microenvironment Drivers of Lethal Prostate Cancer for Better Patient Stratification, Disease Tracking and Drug Target Discovery
2019
Research Grant
Up-Front Psma Alliance: Using Theranostics Early to Eradicate Prostate Cancer and Developing Novel Startegies for Psma-Negative Disease
2017
Conference Proceedings
Lutetium-177 PSMA (LuPSMA) theranostics phase II trial: Efficacy, safety and QoL in patients with castrate-resistant prostate cancer treated with LuPSMA
DOI: 10.1093/annonc/mdx370.0022017
Research Grant
Combination of Radionuclide 177lu-Psma Therapy With Pembrolizumab in Patients With Metastatic Castration-Resistant Prostate Cancer (Mcrpc)
RECENT SCHOLARLY WORKS
2026
Journal article
Clonal hematopoiesis after 177Lu-PSMA-617 radioligand therapy in prostate cancer.
DOI: 10.1158/1078-0432.CCR-25-40012025
Journal article
1637P FDG PET/CT response as a predictive biomarker of long-term outcomes and patterns of recurrence to immune checkpoint inhibitor (ICI) therapy in unresectable cutaneous melanoma
DOI: 10.1016/j.annonc.2025.08.22652025
Journal article
LBA86 Randomised phase III trial of androgen deprivation therapy (ADT) with radiation therapy with or without enzalutamide for high risk, clinically localised prostate cancer: ENZARAD (ANZUP 1303)
DOI: 10.1016/j.annonc.2025.09.1022025
Conference Proceedings
2391P LuPARP: Phase I trial of [177Lu]Lu-PSMA-617 (LuPSMA) and olaparib in patients (pts) with metastatic castration resistant prostate cancer (mCRPC)
DOI: 10.1016/j.annonc.2025.08.30072025
Journal article
115O PROPOSE: Predicting phase I trial fitness using patient-reported outcomes and a clinician-completed prognostic index
DOI: 10.1016/j.esmoop.2025.1054682025
Journal article
Lutetium-177–PSMA-617 or cabazitaxel in metastatic prostate cancer: circulating tumor DNA analysis of the randomized phase 2 TheraP trial
DOI: 10.1038/s41591-025-03704-92025
Journal article
Clonal hematopoiesis (CH) in participants with metastatic castration-resistant prostate cancer (mCRPC) receiving 177 Lu-PSMA-617 or cabazitaxel: An exploratory post-hoc analysis of a randomized phase II trial (TheraP; ANZUP 1603).
DOI: 10.1200/jco.2025.43.16_suppl.5020
RECENT PROJECTS
2019
Research Grant
Up-Front Psma Alliance: Using Theranostics Early to Eradicate Prostate Cancer and Developing Novel Strategies for Psma-Negative Disease